Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07UBR
|
||||
| Former ID |
DNC006886
|
||||
| Drug Name |
Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H20N2O3
|
||||
| Canonical SMILES |
C1C(NC(C(=O)O1)CC2=CC=CC=C2)C(=O)NCC3=CC=CC=C3
|
||||
| InChI |
1S/C19H20N2O3/c22-18(20-12-15-9-5-2-6-10-15)17-13-24-19(23)16(21-17)11-14-7-3-1-4-8-14/h1-10,16-17,21H,11-13H2,(H,20,22)/t16-,17-/m0/s1
|
||||
| InChIKey |
ORMAGLLOPOBCBO-IRXDYDNUSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Voltage-dependent T-type calcium channel subunit alpha-1H | Target Info | Inhibitor | [1] | |
| Voltage-dependent T-type calcium channel alpha-1G subunit | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | MAPK signaling pathway | ||||
| Calcium signaling pathway | |||||
| Circadian entrainmenthsa04010:MAPK signaling pathway | |||||
| Circadian entrainment | |||||
| Type II diabetes mellitus | |||||
| PANTHER Pathway | Endogenous cannabinoid signaling | ||||
| GABA-B receptor II signaling | |||||
| Nicotine pharmacodynamics pathway | |||||
| Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| PathWhiz Pathway | Muscle/Heart ContractionPW000564:Muscle/Heart Contraction | ||||
| Reactome | NCAM1 interactionsR-HSA-419037:NCAM1 interactions | ||||
| WikiPathways | Corticotropin-releasing hormone | ||||
| NCAM signaling for neurite out-growthWP1866:NCAM signaling for neurite out-growth | |||||
| Nicotine Activity on Chromaffin Cells | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2006 Oct 1;16(19):5244-8. Epub 2006 Jul 28.Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.